Drug intelligence / Profile preview

JV201

Development stage: Preclinical
Lead developer: Juvensis Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intravenous

Overview

JV201 is an adeno-associated virus (AAV)-based gene therapy designed to treat chronic kidney disease (CKD) by targeting the telomerase reverse transcriptase (TERT) pathway. Developed by Juvensis Therapeutics, the therapy employs precision telomere regulation technology to modulate telomere length and function within renal tissues. By addressing cellular senescence—a key driver of kidney aging and fibrosis—JV201 aims to preserve renal function and slow disease progression. As of early 2026, the candidate is in the preclinical stage, undergoing CMC (Chemistry, Manufacturing, and Controls) and toxicology evaluation.

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on JV201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JV201.

Explore the full profile